Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Stamulumab, an antibody targeting MSTN.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Milatuzumab, an antibody targeting CD74.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Lumretuzumab, an antibody targeting HER3.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Elgemtumab, an antibody targeting HER3.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Flotetuzumab, an antibody targeting IL3RA × CD3E.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Cibisatamab, an antibody targeting CEACAM5 × CD3E.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Reozalimab, an antibody targeting PD-1 × PD-L1.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Briquilimab, an antibody targeting KIT.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Izeltabart, an antibody targeting ADAM9.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Pamvatamig, an antibody targeting MET × EGFR.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Bezetabart, an antibody targeting CD74.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Teneliximab, an antibody targeting TNFRSF5.